Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

Efficacy, Safety and Satisfaction of the New Pen Needle 33 Gauge x 4 mm. (AGO01)

This study has been completed.
Sponsor:
Collaborator:
Artsana SpA
Information provided by (Responsible Party):
Antonio Nicolucci, Consorzio Mario Negri Sud
ClinicalTrials.gov Identifier:
NCT01745549
First received: December 5, 2012
Last updated: March 17, 2014
Last verified: March 2014
History of Changes
  Purpose

During the last years, even more little needles are used for the injection of sub cutaneous insulin, for the diabetes therapy.

The aim of this study is to evaluate the non inferiority of a new needle, smaller than another needle, in terms of hematic levels od fructosamine, an indicator of glycemic control.


Condition Intervention
Type 1 Diabetes
Type 2 Diabetes
 Device: Needle for insulin pen, 4 mm long and with a diameter of 33 gauge
Device: Needle for insulin pen, 4 mm long and with a diameter of 32 gauge

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Efficacy, Safety and Satisfaction of the New Pen Needle 33G x 4 mm 33G x 4 mm: Cross-over Randomized Controlled Clinical Trial. Studio AGO 01

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Consorzio Mario Negri Sud:

Primary Outcome Measures:
  • hematic fructosamine levels [ Time Frame: Change from baseline in fructosamine levels after 3 weeks of treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • mean amplitude of glucose excursions (MAGE) [ Time Frame: Change from baseline in MAGE after 3 weeks of treatment ] [ Designated as safety issue: No ]
  • pain [ Time Frame: questionnaire at the end of the treatments (at 6 weeks) ] [ Designated as safety issue: No ]
    visual analogic scale (VAS) 1-10

  • leakage at the site injection [ Time Frame: number of episodes of leakage during the treatment (3 weeks) ] [ Designated as safety issue: No ]
    visual scale

  • hypoglycemia [ Time Frame: number of episodes of hypoglycemia during the treatment (3 weeks) ] [ Designated as safety issue: Yes ]
  • insulin dosage [ Time Frame: Change from baseline in insulin dosage after 3 weeks of treatment ] [ Designated as safety issue: No ]
  • patient's weight [ Time Frame: Change from baseline in weight after 3 weeks of treatment ] [ Designated as safety issue: No ]
  • patient's satisfaction [ Time Frame: questionnaire at the end of the treatments (at 6 weeks) ] [ Designated as safety issue: No ]
    VAS scale
Enrollment: 87
Study Start Date: December 2012
Study Completion Date: November 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: needle 4 mm gauge 33
Needle for insulin pen, 4 mm long and with a diameter of 33 gauge (the smaller needle)
 Device: Needle for insulin pen, 4 mm long and with a diameter of 33 gauge
Active Comparator: needle 4 mm gauge 32
Needle for insulin pen, 4 mm long and with a diameter of 32 gauge
 Device: Needle for insulin pen, 4 mm long and with a diameter of 32 gauge

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients with type 1 or type 2 diabetes
  • both males and females
  • age >=18 anni
  • insulin treatment from at least 6 months
  • signed informed consent

Exclusion Criteria:

  • pregnancy
  • incapacity for filling in the questionnaires
  • every illness or condition that, according to the investigator, could interfere with the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01745549

Locations
Italy
UO Malattie Metaboliche e Diabetologia - Ospedale di Treviglio-Caravaggio
Treviglio, BG, Italy, 24047
UO Diabetologia per Trattamento e Educazione dei Diabetici - Spedali Civili di Brescia
Brescia, BS, Italy, 25123
U.O.S. Diabetologia e Malattie Metaboliche - PO Cantù - Mariano Comense
Mariano Comense, CO, Italy, 22066
Struttura Complessa Dietologia-Diabetologia Malattie Metaboliche - Ospedale Pertini
Roma, RM, Italy, 00157
Sponsors and Collaborators
Consorzio Mario Negri Sud
Artsana SpA
Investigators
Study Chair: Antonio Nicolucci, MD Consorzio Mario Negri Sud
  More Information

No publications provided

Responsible Party: Antonio Nicolucci, Dr Antonio Nicolucci, MD, Consorzio Mario Negri Sud
ClinicalTrials.gov Identifier: NCT01745549     History of Changes
Other Study ID Numbers: AGO01
Study First Received: December 5, 2012
Last Updated: March 17, 2014
Health Authority: Italy: Ministry of Health

Keywords provided by Consorzio Mario Negri Sud:
diabetes
insulin therapy
needle

Additional relevant MeSH terms:
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Insulin
 Insulin, Globin Zinc
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on February 27, 2015